BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35992379)

  • 1. Jagged-1 is induced by mTOR inhibitors in renal cancer cells through an Akt/ALK5/Smad4-dependent mechanism.
    Danielpour D; Corum S; Leahy P; Bangalore A
    Curr Res Pharmacol Drug Discov; 2022; 3():100117. PubMed ID: 35992379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation.
    Song K; Wang H; Krebs TL; Danielpour D
    EMBO J; 2006 Jan; 25(1):58-69. PubMed ID: 16362038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming Growth Factor β1-induced Apoptosis in Podocytes via the Extracellular Signal-regulated Kinase-Mammalian Target of Rapamycin Complex 1-NADPH Oxidase 4 Axis.
    Das R; Xu S; Nguyen TT; Quan X; Choi SK; Kim SJ; Lee EY; Cha SK; Park KS
    J Biol Chem; 2015 Dec; 290(52):30830-42. PubMed ID: 26565025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NVP-BEZ235 Inhibits Renal Cell Carcinoma by Targeting TAK1 and PI3K/Akt/mTOR Pathways.
    Li B; Zhang X; Ren Q; Gao L; Tian J
    Front Pharmacol; 2021; 12():781623. PubMed ID: 35082669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells.
    van der Poel HG
    J Urol; 2004 Oct; 172(4 Pt 1):1333-7. PubMed ID: 15371835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta.
    Rahimi RA; Andrianifahanana M; Wilkes MC; Edens M; Kottom TJ; Blenis J; Leof EB
    Cancer Res; 2009 Jan; 69(1):84-93. PubMed ID: 19117990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical role of a survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells.
    Song K; Shankar E; Yang J; Bane KL; Wahdan-Alaswad R; Danielpour D
    PLoS One; 2013; 8(5):e61896. PubMed ID: 23658701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity.
    Liang M; Lv J; Chu H; Wang J; Chen X; Zhu X; Xue Y; Guan M; Zou H
    J Dermatol Sci; 2014 Nov; 76(2):104-11. PubMed ID: 25258031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian Target of Rapamycin (mTOR) Regulates Transforming Growth Factor-β1 (TGF-β1)-Induced Epithelial-Mesenchymal Transition via Decreased Pyruvate Kinase M2 (PKM2) Expression in Cervical Cancer Cells.
    Cheng KY; Hao M
    Med Sci Monit; 2017 Apr; 23():2017-2028. PubMed ID: 28446743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
    Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction.
    Kakiuchi Y; Yurube T; Kakutani K; Takada T; Ito M; Takeoka Y; Kanda Y; Miyazaki S; Kuroda R; Nishida K
    Osteoarthritis Cartilage; 2019 Jun; 27(6):965-976. PubMed ID: 30716534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
    Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
    Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of Jagged/Notch pathway abrogates transforming growth factor β2-induced epithelial-mesenchymal transition in human retinal pigment epithelium cells.
    Chen X; Xiao W; Liu X; Zeng M; Luo L; Wu M; Ye S; Liu Y
    Curr Mol Med; 2014 May; 14(4):523-34. PubMed ID: 24694299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Good or not good: Role of miR-18a in cancer biology.
    Kolenda T; Guglas K; Kopczyńska M; Sobocińska J; Teresiak A; Bliźniak R; Lamperska K
    Rep Pract Oncol Radiother; 2020; 25(5):808-819. PubMed ID: 32884453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
    Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aberrant Activation Mechanism of TGF-β Signaling in Epithelial-mesenchymal Transition].
    Yuki R
    Yakugaku Zasshi; 2021; 141(11):1229-1234. PubMed ID: 34719542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROS induces epithelial-mesenchymal transition via the TGF-β1/PI3K/Akt/mTOR pathway in diabetic nephropathy.
    Lu Q; Wang WW; Zhang MZ; Ma ZX; Qiu XR; Shen M; Yin XX
    Exp Ther Med; 2019 Jan; 17(1):835-846. PubMed ID: 30651870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells.
    Le Gendre O; Sookdeo A; Duliepre SA; Utter M; Frias M; Foster DA
    Mol Cancer Res; 2013 May; 11(5):474-81. PubMed ID: 23443316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pterostilbene alleviates fructose-induced renal fibrosis by suppressing TGF-β1/TGF-β type I receptor/Smads signaling in proximal tubular epithelial cells.
    Gu TT; Chen TY; Yang YZ; Zhao XJ; Sun Y; Li TS; Zhang DM; Kong LD
    Eur J Pharmacol; 2019 Jan; 842():70-78. PubMed ID: 30336139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.